Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment

Chinese Medical Journal

Volumn 120, Issue 9, 2007, Pages 782-786

  Jiang, Xiao ^a   Sheng, Hai Hui ^b   Lin, Gang ^c   Li, Jian ^c   Lu, Xin Zheng ^a   Cheng, Yun Lin ^a   Huang, Jun ^a   Xiao, Hua Sheng ^b   Zhan, Yi Yang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b National Engineering Center for Biochip   (China)

^c Dongtai People's Hospital of Jiangsu Province   (China)

Author keywords

Diuretic; Essential hypertension; Gene chip; Renin angiotensin aldosterone system; Single nucleotide polymorphism

Indexed keywords

ALDOSTERONE SYNTHASE; DIPEPTIDYL CARBOXYPEPTIDASE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHINESE; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DNA POLYMORPHISM; DRUG RESPONSE; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENE TECHNOLOGY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROPROCESSOR; MONOTHERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 34248654393     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200705010-00009     Document Type: Article

References (21)

1. Wu SJ, Chiang FT, Chen WJ, Liu PH, Hsu KL, Hwang JJ, et al. Three single-nucleotide polymorphisms of the angiotensinogen gene and susceptibility to hypertension: single locus genotype vs. haplotype analysis. Physiol Genomics 2004; 17: 79-86.
2. Brand-Herrmann SM, Kopke K, Reichenberger F, Schmidt-Petersen K, Reineke T, Paul M, et al. Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. J Hypertens 2004; 22: 1289-1297.
3. Jiang Z, Zhao W, Yu F, Xu G. Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Chin Med J 2001; 114: 1249-1251.
4. Agachan B, Isbir T, Yilmaz H, Akoglu E. Angiotensin converting enzyme I/ D, angiotensinogen T174M-M235T and angiotensin II type1 receptor A1166C gene polymorphisms in Turkish hypertensive patients. Exp Mol Med 2003; 35: 545-549.
5. Sugimoto K, Kat suya T, Ohkubo T, Hozawa A, Yamamoto K, Matsuo A, et al. Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension: the Ohasama Study. Hypertens Res 2004; 27: 551-556.
6. Xu Q, Wang YH, Tong WJ, Gu ML, Wu G, Buren B, et al. Interaction and relationship between angiotensin converting enzyme gene and environmental factors predisposing to essential hypertension in Mongolian population of China. Biomed Environ Sci 2004; 17: 177-186.
7. Brand E, Chatelain N, Mulatero P, Fery I, Curnow K, Jeunemaitre X, et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998; 32:198-204.
8. Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, et al. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens 2004; 17: 8-13.
9. Kurland L, Melhus H, Karlsson J, Kahan T, Milmqvist K, Ohman P, et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002; 15: 387-393.
10. Woodiwiss AJ, Nkeh B, Samani NJ, Badenhorst D, Maseko M, Tiago AD, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. J Hypertens 2006; 24:1057-1064.
11. Frazier L, Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic. Pharmacogenomics J 2004; 4: 17-23.
12. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T, et al. A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenomics 2003; 13: 7-17.
13. Yanai K, Saito T, Hirota K, Kobayashi H, Murakami K, Fukamizu A. Molecular variation of the human angiotensinogen core promoter element located between the TATA box and transcription initiation site affects its transcriptional activity. J Biol Chem 1997; 272: 30558-30562.
14. Wu SJ, Chiang FT, Jiang JR, Hsu KL, Chern TH, Tseng YZ. The G-217A variant of the angiotensinogen gene affects basal transcription and is associated with hypertension in a Taiwanese population. J Hypertens 2003; 21: 2061-2067.
15. Hunt SC, Cook NR, Oberman A, Cutler JA, Hennekens CH, Allender PS, et al. Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension: trials of hypertension prevention, phase II. Hypertension 1998; 32: 393-401.
16. Matsubara M, Kikuya M, Ohkubo T, Metoki H, Omori F, Fujiwara T, et al. Aldosterone synthase gene (CYP11B2) C-334T polymorphism, ambulatory blood pressure and nocturnal decline in blood pressure in the general Japanese population: the Ohasama Study. J Hypertens 2001; 19: 2179-2184.
17. Casiglia E, Tikhonoff V, Mazza A, Rynkiewicz A, Limon J, Caffi S, et al. C-344T polymorphism of the aldosterone synthase gene and blood pressure in the elderly: a population-based study. J Hypertens 2005; 23: 1991-1996.
18. Ortlepp JR, Hanrath P, Mevissen V, Kiel G, Borggrefe M, Hoffmann R. Variants of the CYP11B2 gene predict response to therapy with candesartan. Eur J Pharmacol 2002; 445: 151-152.
19. Brand E, Schorr U, Ringel J, Beige J, Distler A, Sharma AM. Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST). J Hypertens 1999; 17: 1563-1567.
20. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E. Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002; 62:1718-1723.
21. Schork NJ. Genetically complex cardiovascular traits. Origins, problems, and potential solutions. Hypertension 1997; 29(1 Pt 2):145-149.